# Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

> **NCT06042647** · PHASE4 · COMPLETED · sponsor: **Dermatology Consulting Services, PLLC** · enrollment: 10 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** 0.01% Halobetasol
- **DRUG:** 0.045% Tazarotene
- **DRUG:** 0.05% Clobetasol Propionate

## Key facts

- **NCT ID:** NCT06042647
- **Lead sponsor:** Dermatology Consulting Services, PLLC
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-13
- **Primary completion:** 2023-11-13
- **Final completion:** 2023-11-13
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06042647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06042647, "Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06042647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*